MedTrace Logo

Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control

NCT02913794 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 541

Last updated 2023-06-12

No results posted yet for this study

Summary

Fimasartan and Rosuvastatin for hypertension and dyslipidemia control

Conditions

Sponsors & Collaborators

  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Hyung-Jin Jung · Boryung Pharmaceutical Co., Ltd

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-11
Primary Completion
2018-03-29
Completion
2018-03-29

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02913794 on ClinicalTrials.gov